news.today
Hello · Register today | LoginHello · My Account[—] [33]
Tech

Demis Hassabis' Isomorphic Labs raises $5 billion for AI drug discovery

Summarised from 3 outlets · Updated 17 Nov, 15:08 · Archive

Isomorphic Labs, the AI drug-discovery startup founded by Demis Hassabis, has raised $5 billion in Series C funding.

Isomorphic Labs, an AI drug-discovery startup founded by Demis Hassabis, has raised $5 billion in Series C funding. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other investors participating. Alphabet's venture divisions GV and Capital G also invested alongside existing backers including Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.

The company builds an AI drug-design engine using simulation models to design medicines. Its work builds on DeepMind's AlphaFold protein-folding AI model and has yielded what it describes as 'positive preclinical results' in oncology and immunology. Isomorphic has struck deals with pharmaceutical companies including Eli Lilly, Novartis, and Johnson & Johnson.

Funding will support development of the drug-design engine and expansion into more types of medicine, with the goal of taking drug candidates to clinical trials. This is Isomorphic's first fundraise since Demis Hassabis left his position as CEO of DeepMind to focus on drug discovery and moved into a chairman role at DeepMind. Bloomberg reported the company was seeking a $50 billion valuation, though Isomorphic did not disclose its new valuation.

Comments (0)

How it is being reported

In this story: Isomorphic Labs · Demis Hassabis · Google DeepMind · Greenoaks · Sequoia Capital · Alphabet · Eli Lilly · Novartis

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log